286OPhase III KEYNOTE-048 study of first-line pembrolizumab...

Annals of Oncology 2019 / 11 Vol. 30; Iss. Supplement

286OPhase III KEYNOTE-048 study of first-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma: Asia vs non-Asia subgroup analysis

Ngamphaiboon, N, Tanaka, K, Hong, R-L, Wan Ishak, W Z, Yen, C-J, Sriuranpong, V, Takahashi, S, Srimuninnimit, V, Yeh, S-P, Oridate, N, Yang, M-H, Nohata, N, Koh, Y, Roy, A, Gumuscu, B, Swaby, R, Tahar
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
30
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz428
Date:
November, 2019
File:
PDF, 101 KB
2019
Conversion to is in progress
Conversion to is failed